References
- Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM97(10), 671–676 (2004).
- Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler.10, 589–595 (2004).
- Oreja-Guevara C, González D, Vila C, de Sola S. Multiple sclerosis spasticity in Spain: the 6E patients’ survey. Mult. Scler.17, S80 (2011).
- Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study. Expert Rev. Pharmacoecon. Outcomes Res.11, 205–213 (2011).
- Hass J. Pathophysiology, assessment and management of multiple sclerosis spasticity: an update. Exp. Rev. Neurother.11(Suppl. 1), 3–8 (2011).
- Farrar JT, Troxel A, Stott CG, Duncombe P. The validity, reliability and clinical importance of changes in spasticity severity measured on a 0–10 numerical rating scale. J. Neurol.254(Suppl. 3), 21 (2007).
- Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0–10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin. Ther.30(5), 974–985 (2008).
- Arroyo R, González-Segura D, Viladrich M. Correlation between quality of life and spasticity in Spanish patients with multiple sclerosis using two different spasticity scales: the CANDLE Study. Presented at: the 28th Congress for the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012.
- Shakespeare DT, Boggild M, Young CA. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev.4, CD001332 (2003).
- Flachenecker P, Zettl U, Essner U, Henze T. Drug treatment of spasticity in multiple sclerosis – a cross-sectional survey in Germany. Presented at: the 28th Congress for the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10–13 October 2012.
- Flachenecker P, Henze T, Hengsbach M, Ehlken B, Zettl UK. Spasticity in multiple sclerosis – a cross-sectional survey in Germany. Mult. Scler.18, S21 (2012).
- Slof J, Gras A. Sativex® in multiple sclerosis spasticity: a cost–effectiveness model. Expert Rev. Pharmacoecon. Outcomes Res.12(4), 525–538 (2012).
- Delgado-Rodríguez M, Llorca J. Bias. J. Epidemiol. Commun. H.58(8), 635–641 (2004).
- Draugalis JR, Plaza CM. Best practices for survey research reports revisited: implications of target population, probability sampling, and response rate. Am. J. Pharm. Educ.73(8), 142 (2009).